Stock chart
Analyses on Enlivex (3)
- March 25, 2026March 25, 2026
- Follow-up
Enlivex: What the Knee Program Still Has to Prove Before Allocetra Moves From Signal to Proof
Enlivex's knee program has already shown a placebo-controlled efficacy signal in an older patient population, but it has not yet shown that this signal has become clean proof in a prospectively defined target population. Phase IIb has to turn responder-population logic into a sh…
E - Follow-up
Enlivex: What Is Actually Accessible to Shareholders After RAIN, the Collateral, and the Note
Enlivex now has a sharp gap between fair value and accessible value: at year-end 2025 the balance sheet carried a huge RAIN and RAIN-option layer, but the immediate cash layer beneath it was only $5.755 million. Since March 2026, part of that exposure already sits inside a secur…
E Enlivex 2025: The Balance Sheet Moved Into RAIN, but the Real Proof Still Sits in the Knee Trial and in Liquidity
Enlivex remained a no-revenue biotech in 2025, but its balance sheet was almost entirely replaced by RAIN and the RAIN option. The central question is no longer just clinical cash burn, but whether fair value in one digital asset can turn into liquidity that supports Phase IIb a…
E
